Changes of Serum HSP90α and CYFR211 Levels and Prognostic Factors in Patients Underwent Radical Gastrectomy Assisted by Epirubicin and Paclitaxel Chemotherapy
Objective To analyze serum HSP90α and CYFR211 levels and prognostic factors of patients underwent radi-cal gastrectomy with epirubicin combined with paclitaxel chemotherapy.Methods 96 patients who underwent radical gastrectomy for gastric cancer were selected and treated with epirubicin combined with paclitaxel through arterial interventional chemotherapy.The serum HSP90α and CYFR211 levels were compared before treatment,after 6 weeks of treatment,and after 12 weeks of treat-ment.The patients were followed up for 2 years,and the progression-free survival(PFS)and overall survival(OS)were counted.The prognosis of patients was evaluated according to the WHO objective evaluation criteria for solid tumors,and they were grouped into a poor prognosis group and a good prognosis group.Univariate analysis and multivariate logistic regression were used to ana-lyze the risk factors affecting the prognosis of patients with radical gastrectomy for gastric cancer.Results After 6 weeks of treat-ment,the levels of serum HSP90α and CYFR211 in the 2 groups were lower than those before treatment(P<0.05),and after 12 weeks of treatment,the levels of serum HSP90α and CYFR211 in the 2 groups were lower than those before treatment and after 6 weeks of treatment(P<0.05);the 6-month,1-and 2-year progression-free survival rates were 58.3%,30.2%,and 20.2%,re-spectively,and the6-month,1-and2-year overall survival rates were 81.2%,63.5%,and 32.6%,respectively,the median PFS and OS were 10 months and 16 months,respectively;the prognosis of patients undergoing radical gastrectomy for gastric cancer was not related to gender,body mass index,surgical blood loss,surgical method,postoperative serious adverse reactions,and the location of gastric cancer(P>0.05),it was related to age,tumor diameter,operation time,extent of gastrectomy,TNM stage,and tumor differentiation(P<0.05);age,tumor diameter,extent of gastrectomy,operation time,TNM stage,and tumor differentiation were independent risk factors for poor prognosis in patients with radical gastrectomy(P<0.05).Conclusion Epirubicin com-bined with paclitaxel through arterial interventional chemotherapy in treating patients with radical gastrectomy for gastric cancer can reduce the levels of serum HSP90α and CYFR211.Age,tumor diameter,gastrectomy range,operation time,TNM staging,and tumor differentiation are independent risk factors for poor prognosis in patients with radical gastrectomy for gastric cancer.
万方数据
维普
